The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data

References

• Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010; 129:154-69; PMID:20561356; http://dx.doi.org/10.1111/j.1365-2567.2009.03225.x
   PubMed Web of Science ®Google Scholar
• Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll‐like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61:1013-21; PMID:12430718
   PubMed Web of Science ®Google Scholar
• Koedel U, Merbt UM, Schmidt C, Angele B, Popp B, Wagner H, Pfister HW, Kirschning CJ. Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses. Am J Pathol 2007; 171:200-13; PMID:17591966; http://dx.doi.org/10.2353/ajpath.2007.060821
   PubMed Web of Science ®Google Scholar
• Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, Schulz-Schaeffer W, Fassbender K. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging 2009; 30:759-68; PMID:17905482; http://dx.doi.org/10.1016/j.neurobiolaging.2007.08.018
   PubMed Web of Science ®Google Scholar
• Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev 2009; 59:278-92; PMID:18822314; http://dx.doi.org/10.1016/j.brainresrev.2008.09.001
   PubMed Web of Science ®Google Scholar
• Marta M, Meier UC, Lobell A. Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun Rev 2009; 8:506-9; PMID:19211042; http://dx.doi.org/10.1016/j.autrev.2009.01.006
   PubMed Web of Science ®Google Scholar
• Qin J, Goswami R, Dawson S, Dawson G. Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J Neurosci Res 2008; 86:2414-22; PMID:18438937; http://dx.doi.org/10.1002/jnr.21692
   PubMed Web of Science ®Google Scholar
• Andersson Å, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, Khademi M, Wallström E, Lobell A, Brundin L, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008; 84:1248-55; PMID:18644848; http://dx.doi.org/10.1189/jlb.1207844
   PubMed Web of Science ®Google Scholar
• Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 2007; 44:999-1010; PMID:16698083; http://dx.doi.org/10.1016/j.molimm.2006.03.007
   PubMed Web of Science ®Google Scholar
• Huizinga R, Linington C, Amor S. Resistance is futile: antineuronal autoimmunity in multiple sclerosis. Trends Immunol 2008; 29:54-60; PMID:18182323; http://dx.doi.org/10.1016/j.it.2007.11.002
   PubMed Web of Science ®Google Scholar
• Martino D, Giovannoni G. Antibasal ganglia antibodies and their relevance to movement disorders. Curr Opin Neurol 2004; 17:425-32; PMID:15247537; http://dx.doi.org/10.1097/01.wco.0000137532.76491.19
   PubMed Web of Science ®Google Scholar
• Huizinga R, Hintzen RQ, Assink K, van Meurs M, Amor S. T-cell responses to neurofilament light protein are part of the normal immune repertoire. Int Immunol 2009:21:433-41; PMID:19240089; http://dx.doi.org/10.1093/intimm/dxp011
   PubMed Web of Science ®Google Scholar
• Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, Fulop T. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimer's Dis 2009; 17:91-103; PMID:19494434
   PubMed Web of Science ®Google Scholar
• Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, Bendotti C, Mora G. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol 2009; 210:73-9; PMID:19307024; http://dx.doi.org/10.1016/j.jneuroim.2009.02.012
   PubMed Web of Science ®Google Scholar
• Ankeny DP, Popovich PG. Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience 2009; 158:1112-21; PMID:18674593; http://dx.doi.org/10.1016/j.neuroscience.2008.07.001
   PubMed Web of Science ®Google Scholar
• Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25:313-9; PMID:12086750; http://dx.doi.org/10.1016/S0166-2236(02)02154-9
   PubMed Web of Science ®Google Scholar
• Seksenyan A, Ron-Harel N, Azoulay D, Cahalon L, Cardon M, Rogeri P, Ko MK, Weil M, Bulvik S, Rechavi G, et al. Thymic involution, a co‐morbidity factor in amyotrophic lateral sclerosis. J Cell Mol Med 2010; 14:2470-82; PMID:19650830; http://dx.doi.org/10.1111/j.1582-4934.2009.00863.x
   PubMed Web of Science ®Google Scholar
• Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis? J Neurol Scie 2008; 265:93-6; PMID:17459415; http://dx.doi.org/10.1016/j.jns.2007.03.012
   PubMed Web of Science ®Google Scholar
• Jummani RR, Okun MS. SYdenham chorea. Arch Neurol 2001; 58:311-3; PMID:11176972; http://dx.doi.org/10.1001/archneur.58.2.311
   PubMed Web of Science ®Google Scholar
• Martino D, Tanner A, Defazio G, Church AJ, Bhatia KP, Giovannoni G, Dale RC. Tracing Sydenham's chorea: historical documents from a British paediatric hospital. Arch Dis Child 2005; 90:507-11; PMID:15851434; http://dx.doi.org/10.1136/adc.2004.057679
   PubMed Web of Science ®Google Scholar
• Osler W. ON chorea and choreiform: affections. Am J Med Sci 1895; 109:316-317; http://dx.doi.org/10.1097/00000441-189503000-00011
   Google Scholar
• Gordon N. Sydenham's chorea, and its complications affecting the nervous system. Brain and Development 2009; 31:11-14; PMID:18558468; http://dx.doi.org/10.1016/j.braindev.2008.05.001
   PubMed Web of Science ®Google Scholar
• Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Lougee L, Dow S, Zamkoff J, Dubbert BK. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155:264-71; PMID:9464208
   PubMed Web of Science ®Google Scholar
• Swedo SE, Leonard HL, Kiessling LS. Speculations on antineuronal antibody-mediated neuropsychiatric disorders of childhood. Pediatrics 1994; 93:323-6; PMID:8121747
   PubMed Web of Science ®Google Scholar
• Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies in movement disorders. Pediatrics 1993; 92:39-43; PMID:8516083
   PubMed Web of Science ®Google Scholar
• Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9:914-20; PMID:12819778; http://dx.doi.org/10.1038/nm892
   PubMed Web of Science ®Google Scholar
• Church A, Dale R, Giovannoni G. Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? Arch Dis Child 2004; 89:611-4; PMID:15210488; http://dx.doi.org/10.1136/adc.2003.031880
   PubMed Web of Science ®Google Scholar
• Pavone P, Bianchini R, Parano E, Incorpora G, Rizzo R, Mazzone L, Trifiletti RR. Anti-brain antibodies in PANDAS versus uncomplicated streptococcal infection. Pediatr Neurol 2004; 30:107-10; PMID:14984902; http://dx.doi.org/10.1016/S0887-8994(03)00413-2
   PubMed Web of Science ®Google Scholar
• Gause C, Morris C, Vernekar S, Pardo-Villamizar C, Grados MA, Singer HS. Antineuronal antibodies in OCD: comparisons in children with OCD-only, OCD+ chronic tics and OCD+ PANDAS. J Neuroimmunol 2009; 214:118-24; PMID:19628285; http://dx.doi.org/10.1016/j.jneuroim.2009.06.015
   PubMed Web of Science ®Google Scholar
• Morer A, Lázaro L, Sabater L, Massana J, Castro J, Graus F. Antineuronal antibodies in a group of children with obsessive–compulsive disorder and Tourette syndrome. J Psychiatr Res 2008; 42:64-8; PMID:17113107; http://dx.doi.org/10.1016/j.jpsychires.2006.09.010
   PubMed Web of Science ®Google Scholar
• Asbahr FR, Negrão AB, Gentil V, Zanetta DM, da Paz JA, Marques-Dias MJ, Kiss MH. Obsessive-compulsive and related symptoms in children and adolescents with rheumatic fever with and without chorea: a prospective 6-month study. Am J Psychiatry 1998; 155:1122-4; PMID:9699708; http://dx.doi.org/10.1176/ajp.155.8.1122
   PubMed Web of Science ®Google Scholar
• Dale RC, Heyman I, Giovannoni G, Church AW. Incidence of anti-brain antibodies in children with obsessive–compulsive disorder. Br J Psychiatry 2005; 187:314-9; PMID:16199788; http://dx.doi.org/10.1192/bjp.187.4.314
   PubMed Web of Science ®Google Scholar
• Leckman JF, Katsovich L, Kawikova I, Lin H, Zhang H, Krönig H, Morshed S, Parveen S, Grantz H, Lombroso PJ, et al. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome. Biol Psychiatry 2005; 57:667-73; PMID:15780855; http://dx.doi.org/10.1016/j.biopsych.2004.12.004
   PubMed Web of Science ®Google Scholar
• Gabbay V, Coffey BJ, Guttman LE, Gottlieb L, Katz Y, Babb JS, Hamamoto MM, Gonzalez CJ. A cytokine study in children and adolescents with Tourette's disorder. Progress Neuro-Psychopharmacol Biol Psychiatry 2009; 33:967-71; PMID:19427348; http://dx.doi.org/10.1016/j.pnpbp.2009.05.001
   PubMed Web of Science ®Google Scholar
• Morer A, Chae W, Henegariu O, Bothwell AL, Leckman JF, Kawikova I. Elevated expression of MCP-1, IL-2 and PTPR-N in basal ganglia of Tourette syndrome cases. Brain Behav Immun 2010; 24:1069-73; PMID:20193755; http://dx.doi.org/10.1016/j.bbi.2010.02.007
   PubMed Web of Science ®Google Scholar
• Cheng YH, Zheng Y, He F, Yang JH, Li WB, Wang ML, Cui DY, Chen Y. Detection of autoantibodies and increased concentrations of interleukins in plasma from patients with Tourette's syndrome. J Mol Neurosci 2012; 48:219-24; PMID:22638859; http://dx.doi.org/10.1007/s12031-012-9811-8
   PubMed Web of Science ®Google Scholar
• Matz J, Krause DL, Dehning S, Riedel M, Gruber R, Schwarz MJ, Müller N. Altered monocyte activation markers in Tourette's syndrome: a case–control study. BMC Psychiatry 2012; 12:29; PMID:22471395; http://dx.doi.org/10.1186/1471-244X-12-29
   PubMed Web of Science ®Google Scholar
• Paz JA, Silva CA, Marques-Dias MJ. Randomized double-blind study with prednisone in Sydenham's chorea. Pediatr Neurol 2006; 34:264-9; PMID:16638499; http://dx.doi.org/10.1016/j.pediatrneurol.2005.08.028
   PubMed Web of Science ®Google Scholar
• Walker AR, Tani LY, Thompson JA, Firth SD, Veasy LG, Bale JF Jr. Rheumatic chorea: relationship to systemic manifestations and response to corticosteroids. J Pediatr 2007; 151:679-83; PMID:18035153; http://dx.doi.org/10.1016/j.jpeds.2007.04.059
   PubMed Web of Science ®Google Scholar
• Fusco C, Ucchino V, Frattini D, Pisani F, Della Giustina E. Acute and chronic corticosteroid treatment of ten patients with paralytic form of Sydenham's chorea. Eur J Paediatr Neurol 2012; 16:373-8; PMID:22197452; http://dx.doi.org/10.1016/j.ejpn.2011.12.005
   PubMed Web of Science ®Google Scholar
• Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol 2005; 20:424-9; PMID:15968928; http://dx.doi.org/10.1177/08830738050200050601
   PubMed Web of Science ®Google Scholar
• Van Immerzeel TD, Van Gilst RM, Hartwig NG. Beneficial use of immunoglobulins in the treatment of Sydenham chorea. Eur J Pediatr 2010; 169:1151-4; PMID:20349351; http://dx.doi.org/10.1007/s00431-010-1172-0
   PubMed Web of Science ®Google Scholar
• Walker K, Brink A, Lawrenson J, Mathiassen W, Wilmshurst JM. Treatment of sydenham chorea with intravenous immunoglobulin. J Child Neurol 2012; 27:147-55; PMID:21868369; http://dx.doi.org/10.1177/0883073811414058
   PubMed Web of Science ®Google Scholar
• Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 2011; 76:294-300; PMID:21242498; http://dx.doi.org/10.1212/WNL.0b013e318207b1f6
   PubMed Web of Science ®Google Scholar
• Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999; 354:1153-8; PMID:10513708; http://dx.doi.org/10.1016/S0140-6736(98)12297-3
   PubMed Web of Science ®Google Scholar
• Nicolson R, Swedo SE, Lenane M, Bedwell J, Wudarsky M, Gochman P. An open trial of plasma exchange in childhood-onset obsessive-compulsive disorder without poststreptococcal exacerbations. J Am Acad Child Adolesc Psychiatry 2000; 39:1313-5; PMID:11026187; http://dx.doi.org/10.1097/00004583-200010000-00020
   PubMed Web of Science ®Google Scholar
• Allen AJ, Leonard HL, Swedo SE. Case study: a new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1995; 34:307-11; PMID:7896671; http://dx.doi.org/10.1097/00004583-199503000-00015
   PubMed Web of Science ®Google Scholar
• Giedd JN, Rapoport JL, Leonard HL, Richter D, Swedo SE. Case study: acute basal ganglia enlargement and obsessive-compulsive symptoms in an adolescent boy. J Am Acad Child Adolesc Psychiatry 1996; 35:913-5; PMID:8768351; http://dx.doi.org/10.1097/00004583-199607000-00017
   PubMed Web of Science ®Google Scholar
• Zykov V, Shcherbina AY, Novikova EB, Shvabrina TV. Neuroimmune aspects of the pathogenesis of Tourette's syndrome and experience in the use of immunoglobulins in children. Neurosci Behav Physiol 2009; 39:635-8; PMID:19621268; http://dx.doi.org/10.1007/s11055-009-9184-9
   PubMedGoogle Scholar
• Hoekstra PJ, Minderaa RB, Kallenberg C. Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. J Clin Psychiatry 2004; 65:537-42; PMID:15119917; http://dx.doi.org/10.4088/JCP.v65n0413
   PubMed Web of Science ®Google Scholar
• Müller N. Anti-inflammatory therapy with a COX-2 inhibitor in Tourette's syndrome. Inflammopharmacology 2004; 12:271-5; PMID:15527551; http://dx.doi.org/10.1163/1568560042342338
   PubMedGoogle Scholar
• Dale RC, Yin K, Ding A, Merheb V, Varadkhar S, McKay D, Singh-Grewal D, Brilot F. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev Med Child Neurol 2011; 53:522-8; PMID:21574989; http://dx.doi.org/10.1111/j.1469-8749.2011.03922.x
   PubMed Web of Science ®Google Scholar
• Peluso S, Antenora A, De Rosa A, Roca A, Maddaluno G, Brescia Morra V, De Michele G. Antiphospholipid-related chorea. Front Neurol 2012; 3:150; PMID:23097646; http://dx.doi.org/10.3389/fneur.2012.00150
   PubMedGoogle Scholar
• Lazurova I, Macejova Z, Benhatchi K, Oetterová M, Antolová E, Asherson RA, Rovensky J. Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea. Clin Rheumatol 2007; 26:2145-7; PMID:17487450; http://dx.doi.org/10.1007/s10067-007-0627-9
   PubMed Web of Science ®Google Scholar
• Bertsias G, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69:2074-82; PMID:20724309; http://dx.doi.org/10.1136/ard.2010.130476
   PubMed Web of Science ®Google Scholar
• Brogna C, Mariotti P, Manna R. Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea. Lupus 2014; 23:1449-51; PMID:25237169; http://dx.doi.org/10.1177/0961203314551084
   PubMed Web of Science ®Google Scholar
• Sandvig I, Barlinn J, Nedregaard B. Skjeldal OH An important differential diagnosis of acute neurological disease. Eur J Paediatr Neurol 2015; 19:211-7; PMID:25596063; http://dx.doi.org/10.1016/j.ejpn.2014.12.004
   PubMed Web of Science ®Google Scholar
• Brinar VV, Habek M. Monophasic acute, recurrent, and multiphasic disseminated encephalomyelitis and multiple sclerosis. Arch Neurol 2008; 65:672-7; PMID:18474748; http://dx.doi.org/10.1001/archneur.65.5.675
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 2007; 20:343-50; PMID:17495631; http://dx.doi.org/10.1097/WCO.0b013e3280be58d8
   PubMed Web of Science ®Google Scholar
• Ishizu T, Minohara M, Ichiyama T, Kira R, Tanaka M, Osoegawa M, Hara T, Furukawa S, Kira J. CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis. J Neuroimmunol 2006; 175:52-8; PMID:16697050; http://dx.doi.org/10.1016/j.jneuroim.2006.03.020
   PubMed Web of Science ®Google Scholar
• Javed A, Khan O. Acute disseminated encephalomyelitis. Handb Clin Neurol 2014; 123:705-17; PMID:25015513
   PubMedGoogle Scholar
• Anlar B, Basaran C, Kose G, Guven A, Haspolat S, Yakut A, Serdaroglu A, Senbil N, Tan H, Karaagaoglu E, et al. Acute disseminated encephalomyelitis in children: outcome and prognosis. Neuropediatrics 2003; 34:194-9; PMID:12973660; http://dx.doi.org/10.1055/s-2003-42208
   PubMed Web of Science ®Google Scholar
• Alexander M, Murthy J. Acute disseminated encephalomyelitis: Treatment guidelines. Ann Indian Acad Neurol 2011; 14:S60; PMID:21847331; http://dx.doi.org/10.4103/0972-2327.83095
   PubMedGoogle Scholar
• Nishikawa M, Ichiyama T, Hayashi T, Ouchi K, Furukawa S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol 1999; 21:583-6; PMID:10465150; http://dx.doi.org/10.1016/S0887-8994(99)00042-9
   PubMed Web of Science ®Google Scholar
• Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 1999; 165:56-61; PMID:10426148; http://dx.doi.org/10.1016/S0022-510X(99)00072-6
   PubMed Web of Science ®Google Scholar
• Feasby T, Banwell B, Benstead T, Bril V, Brouwers M, Freedman M, Hahn A, Hume H, Freedman J, Pi D, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007; 21:S57-107; PMID:17397768; http://dx.doi.org/10.1016/j.tmrv.2007.01.002
   PubMed Web of Science ®Google Scholar
• Imataka G, Arisaka O. An infant with steroid-refractory cytomegalovirus-associated ADEM who responded to immunoglobulin therapy. Eur Rev Med Pharmacol Sci 2014; 18:2148-51; PMID:25070820
   PubMed Web of Science ®Google Scholar
• Hahn JS, Siegler DJ, Enzmann D. Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis. Neurology 1996; 46:1173-4; PMID:8780119; http://dx.doi.org/10.1212/WNL.46.4.1173
   PubMed Web of Science ®Google Scholar
• Mariotti P, Batocchi AP, Colosimo C, Lo Monaco M, Caggiula M, Colitto F, Tonali PA, Guzzetta F. Multiphasic demyelinating disease involving central and peripheral nervous system in a child. Neurology 2003; 60:348-9; PMID:12552065; http://dx.doi.org/10.1212/01.WNL.0000044051.79305.DD
   PubMed Web of Science ®Google Scholar
• Kanter D, Horensky D, Sperling RA, Kaplan JD, Malachowski ME, Churchill WH Jr. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology 1995; 45:824-7; PMID:7723979; http://dx.doi.org/10.1212/WNL.45.4.824
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878-86; PMID:10589540; http://dx.doi.org/10.1002/1531-8249(199912)46:6%3c878::AID-ANA10%3e3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Weinshenker BG. Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. J Clin Apher 2001; 16:39-42; PMID:11309833; http://dx.doi.org/10.1002/jca.1010
   PubMed Web of Science ®Google Scholar
• Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58(1):143-6; PMID:11781423; http://dx.doi.org/10.1212/WNL.58.1.143
   PubMed Web of Science ®Google Scholar
• Llufriu S, Castillo J, Blanco Y, Ramió-Torrentà L, Río J, Vallès M, Lozano M, Castellà MD, Calabia J, Horga A, et al. Plasma exchange for acute attacks of CNS demyelination Predictors of improvement at 6 months. Neurology 2009; 73:949-53; PMID:19770470; http://dx.doi.org/10.1212/WNL.0b013e3181b879be
   PubMed Web of Science ®Google Scholar
• Brunot S, Vukusic S, Fromont A, Couvreur G, Mousson C, Giroud M, Confavreux C, Moreau T. [Plasma exchanges in severe and acute inflammatory demyelinating attacks of the central nervous system]. Presse Med 2011; 40:e271-8; PMID:21353760; http://dx.doi.org/10.1016/j.lpm.2010.11.022
   PubMedGoogle Scholar
• Miyazawa R, Hikima A, Takano Y, Arakawa H, Tomomasa T, Morikawa A. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Brain Dev 2001; 23:424-6; PMID:11578855; http://dx.doi.org/10.1016/S0387-7604(01)00256-X
   PubMed Web of Science ®Google Scholar
• Bennetto L, Totham A, Healy P, Massey E, Scolding N. Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases. J Neurol 2004; 251:1515-21; PMID:15645353; http://dx.doi.org/10.1007/s00415-004-0588-8
   PubMed Web of Science ®Google Scholar
• RamachandranNair R, Parameswaran M, Girija A. Acute disseminated encephalomyelitis treated with plasmapheresis. Singapore Med J 2005; 46:561; PMID:16172778
   PubMedGoogle Scholar
• Khurana DS, Melvin JJ, Kothare SV, Valencia I, Hardison HH, Yum S, Faerber EN, Legido A. Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 2005; 116:431-6; PMID:16061599; http://dx.doi.org/10.1542/peds.2004-2038
   PubMed Web of Science ®Google Scholar
• Koziolek M, Mühlhausen J, Friede T, Ellenberger D, Sigler M, Huppke B, Gärtner J, Müller GA, Huppke P. Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease. Blood Purif 2013; 36:92-7; PMID:24021839
   PubMed Web of Science ®Google Scholar
• Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 2001; 56:1313-8; PMID:11376180; http://dx.doi.org/10.1212/WNL.56.10.1313
   PubMed Web of Science ®Google Scholar
• Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol 2014; 13:936-48; PMID:25142460; http://dx.doi.org/10.1016/S1474-4422(14)70093-6
   PubMed Web of Science ®Google Scholar
• Yeh EA, Chitnis T, Krupp L, Ness J, Chabas D, Kuntz N, Waubant E; US Network of Pediatric Multiple Sclerosis Centers of Excellence. Pediatric multiple sclerosis. Nat Revi Neurol 2009; 5:621-31; PMID:19826402; http://dx.doi.org/10.1038/nrneurol.2009.158
   PubMed Web of Science ®Google Scholar
• Spalice A, Parisi P, Papetti L, Nicita F, Ursitti F, Del Balzo F, Properzi E, Verrotti A, Ruggieri M, Iannetti P. Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update. Curr Neuropharmacol 2010; 8:135-48; PMID:21119885; http://dx.doi.org/10.2174/157015910791233141
   PubMed Web of Science ®Google Scholar
• Narula S, Banwell B. Treatment of multiple sclerosis in children and its challenges. Presse Med 2015; 44(4 Pt 2):e153-8; http://dx.doi.org/10.1016/j.lpm.2014.10.018; Epub 2015 Mar 3.
   Google Scholar
• Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006; 2:201-11; PMID:16932551; http://dx.doi.org/10.1038/ncpneuro0154
   PubMedGoogle Scholar
• Colombo M, Dono M, Gazzola P, Roncella S, Valetto A, Chiorazzi N, Mancardi GL, Ferrarini M. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000; 164:2782-9; PMID:10679121; http://dx.doi.org/10.4049/jimmunol.164.5.2782
   PubMed Web of Science ®Google Scholar
• Chabas D, Green AJ, Waubant E. Pediatric multiple sclerosis. NeuroRx 2006; 3(2):264-75; PMID:16554264; http://dx.doi.org/10.1016/j.nurx.2006.01.011
   PubMedGoogle Scholar
• Chitnis T, Green AJ, Waubant E. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler J 2012; 18:116-27; PMID:22146610; http://dx.doi.org/10.1177/1352458511430704
   PubMed Web of Science ®Google Scholar
• Iannetti P, Marciani MG, Spalice A, Spanedda F, Raucci U, Trasimeni G, Gualdi GF, Bernardi G. Primary CNS demyelinating diseases in childhood: multiple sclerosis. Childs Nerv Syst 1996; 12:149-54; PMID:8697458; http://dx.doi.org/10.1007/BF00266819
   PubMed Web of Science ®Google Scholar
• Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, Ramanathan M, Belman A, Chabas D, Gorman MP, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol 2011; 68(4):437-44; PMID:21149803; http://dx.doi.org/10.1001/archneurol.2010.325
   PubMed Web of Science ®Google Scholar
• Johnston J, So TY. First-line disease-modifying therapies in paediatric multiple sclerosis. Drugs 2012; 72:1195-211; PMID:22642799; http://dx.doi.org/10.2165/11634010-000000000-00000
   PubMed Web of Science ®Google Scholar
• Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2010; 74:1463-70; PMID:20439849; http://dx.doi.org/10.1212/WNL.0b013e3181dc1ae0
   PubMed Web of Science ®Google Scholar
• Kornek B, Bernert G, Rostasy K, Mlczoch E, Feucht M, Prayer D, Vass K, Seidl R. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis. Neuropediatrics 2011; 42:7-12; PMID:21557144; http://dx.doi.org/10.1055/s-0031-1275345
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Afzali P, Abtahi SH, Ramagopalan SV, Nourian SM, Murray RT, Fereidan-Esfahani M. Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis. Eur J Paediatr Neurol 2014; 18:119-25; PMID:24139067; http://dx.doi.org/10.1016/j.ejpn.2013.09.001
   PubMed Web of Science ®Google Scholar
• Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009; 72:2076-82; PMID:19439723; http://dx.doi.org/10.1212/WNL.0b013e3181a8164c
   PubMed Web of Science ®Google Scholar
• Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol 2008; 65:1655-8; PMID:19064754; http://dx.doi.org/10.1001/archneur.65.12.1655
   PubMed Web of Science ®Google Scholar
• Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol 2009; 13:67-71; PMID:18406645; http://dx.doi.org/10.1016/j.ejpn.2008.01.007
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, Filippi M, Moiola L, Rocca MA, Rottoli M, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 2010; 75:912-7; PMID:20820002; http://dx.doi.org/10.1212/WNL.0b013e3181f11daf
   PubMed Web of Science ®Google Scholar
• Torisu H, Hara T. [Clinical features of pediatric multiple sclerosis: epidemiology and treatment]. Nihon Rinsho 2014; 72:2061-6; PMID:25518393
   PubMedGoogle Scholar
• Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol disorders 2010; 3:293-9; PMID:21179619; http://dx.doi.org/10.1177/1756285610381526
   PubMedGoogle Scholar
• Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366:1870-80; PMID:22591293; http://dx.doi.org/10.1056/NEJMoa1107829
   PubMed Web of Science ®Google Scholar
• Zettl UK, Stüve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 2012; 11:167-73; PMID:21619943; http://dx.doi.org/10.1016/j.autrev.2011.05.008
   PubMed Web of Science ®Google Scholar
• Absoud M, Lim MJ, Appleton R, Jacob A3, Kitley J, Leite MI, Pike MG, Vincent A, Wassmer E, Waters P, Woodhall M, Hemingway C, Palace J. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry 2015; 86(4):470-2; http://dx.doi.org/10.1136/jnnp-2014-308550; Epub 2014 Aug 4.
   Google Scholar
• Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64:1270-2; PMID:15824362; http://dx.doi.org/10.1212/01.WNL.0000159399.81861.D5
   PubMed Web of Science ®Google Scholar
• Cree B. Acute inflammatory myelopathies. Handbook Clin Neurol 2013; 122:613-67
   Google Scholar
• Longoni G, Banwell B, Filippi M, Yeh EA. Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm 2014; 1:e46; PMID:25520954; http://dx.doi.org/10.1212/NXI.0000000000000046
   PubMedGoogle Scholar
• Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D; Aegis of French National Observatory of Multiple Sclerosis. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 2013; 84:511-6; PMID:23138769; http://dx.doi.org/10.1136/jnnp-2012-303121
   PubMed Web of Science ®Google Scholar
• Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007; 13:256-9; PMID:17439893; http://dx.doi.org/10.1177/1352458506070732
   PubMed Web of Science ®Google Scholar
• Winer J. An Update in Guillain-Barré Syndrome. Autoimmune Dis 2014; 2014:793024; PMID:24511391; http://dx.doi.org/10.1155/2014/793024
   PubMedGoogle Scholar
• Hartung HP, Willison HJ, Kieseier BC. Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome. Curr Opin Neurol 2002; 15:571-7; PMID:12352001; http://dx.doi.org/10.1097/00019052-200210000-00008
   PubMed Web of Science ®Google Scholar
• Group G.B.S.S.T. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341:586-90; PMID:8094828
   PubMed Web of Science ®Google Scholar
• Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev 2012; 8:Cd001446; PMID:22895921
   PubMed Web of Science ®Google Scholar
• Mark B, et al. Plasmapheresis in idiopathic inflammatory polyradiculoneuropathy. in Waubant. 1980. LIPPINCOTT-RAVEN PUBL 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106.
   Google Scholar
• Schooneman F, et al. Plasma exchange in Guillain-Barré syndrome: Ten cases. Plasma Ther 1981; 2:117-21
   Google Scholar
• Valbonesi M. Garelli S, Mosconi L, Zerbi D, Celano I. Plasma Exchange as a Therapy for Guillain‐Barré Syndrome with Immune Complexes. Vox Sang 1981; 41:74-8; PMID:7331282; http://dx.doi.org/10.1111/j.1423-0410.1981.tb01017.x
   PubMed Web of Science ®Google Scholar
• The Guillain-Barre syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985; 35:1096-104; PMID:4022342; http://dx.doi.org/10.1212/WNL.35.8.1096
   PubMed Web of Science ®Google Scholar
• McKhann G, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. Plasmapheresis and guillain‐barré syndrome: Analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988; 23:347-53; PMID:3382169; http://dx.doi.org/10.1002/ana.410230406
   PubMed Web of Science ®Google Scholar
• Van der Meché F, Schmitz P. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326:1123-9; PMID:1552913; http://dx.doi.org/10.1056/NEJM199204233261705
   PubMed Web of Science ®Google Scholar
• Ravasio A, Pasquinelli M, Curr∫ Dossi B, Neri W, Guidi C, Gessaroli M, Rasi F, Fabbri R, Mazzini G, et al. High dose intravenous immune globulins and plasma exchange in Guillain-Barre Syndrome. Ital J Neurol Sci 1995; 16:487-92; PMID:8749707; http://dx.doi.org/10.1007/BF02229327
   PubMedGoogle Scholar
• Latov N. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the quality standards subcommittee of the American academy of neurology. Neurology 2004; 62:1653-4; PMID:15136711; http://dx.doi.org/10.1212/WNL.62.9.1653-a
   PubMed Web of Science ®Google Scholar
• Gürses N, Uysal S, Cetinkaya F, Işlek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995; 27:241-3; PMID:8539548; http://dx.doi.org/10.3109/00365549509019016
   PubMed Web of Science ®Google Scholar
• Singhi SC, Jayshree M, Singhi P, Banerjee S, Prabhakar S. Intravenous immunoglobulin in very severe childhood Guillain-Barre syndrome. Ann Trop Paediatr 1999; 19:167-74; PMID:10690257; http://dx.doi.org/10.1080/02724939992491
   PubMed Web of Science ®Google Scholar
• Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics 2005; 116:8-14; PMID:15995024; http://dx.doi.org/10.1542/peds.2004-1324
   PubMed Web of Science ®Google Scholar
• Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM. Intravenous immunoglobulin as therapy for pediatric Guillain-Barre syndrome. J Child Neurol 1997; 12:376-80; PMID:9309521; http://dx.doi.org/10.1177/088307389701200607
   PubMed Web of Science ®Google Scholar
• El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barre syndrome: a randomized study. Crit Care 2011; 15:R164; PMID:21745374; http://dx.doi.org/10.1186/cc10305
   PubMedGoogle Scholar
• Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain‐Barré syndrome. Cochrane Library 2013; 2:CD008630; PMID:23450584
   PubMedGoogle Scholar
• Van Doorn PA. Treatment of Guillain‐Barré syndrome and CIDP. J Peripher Nerv Sys 2005; 10:113-27; PMID:15958124; http://dx.doi.org/10.1111/j.1085-9489.2005.0010203.x
   PubMed Web of Science ®Google Scholar